Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Paclitaxel Poliglumex (CT-2103)/Carboplatin vs Paclitaxel/Carboplatin for the Treatment of Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer (NSCLC) in Women With Estradiol >30 pg/mL

NCT00551733 is registered in ClinicalTrials.gov with CTI BioPharma as lead sponsor.

NCT NCT00551733
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00551733 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Paclitaxel Poliglumex (CT-2103)/Carboplatin vs Paclitaxel/Carboplatin for the Treatment of Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer (NSCLC) in Women With Estradiol >30 pg/mL
Lead sponsor
CTI BioPharma
Phase
Phase 3
Overall status
Terminated
Start date
August 31, 2007
Completion date
December 25, 2007
Enrollment
450 (estimated)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer